Clare Loane1,2,3, Marios Politis1,2, Zinovia Kefalopoulou4, Natalie Valle-Guzman5, Gesine Paul6, Hakan Widner7, Thomas Foltynie4, Roger A Barker8,9, Paola Piccini1. 1. Neurology Imaging Unit, Hammersmith Hospital, Imperial College London, London, UK. 2. Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK. 3. Memory Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. 4. Sobell Department of Motor Neuroscience, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England. 5. John Van Geest Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK. 6. Translational Neurology Group, Department of Clinical Sciences, Wallenberg Neuroscience Center, Lund University, Lund, Sweden. 7. Division of Neurology, Department of Clinical Sciences, Lund University, Skane University Hospital, Sweden. 8. Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK. 9. MRC Cognition and Brian Sciences Unit, University of Cambridge, Cambridge, UK.
Abstract
BACKGROUND: Measuring microstructure alterations with diffusion tensor imaging in PD is potentially a valuable tool to use as a biomarker for early diagnosis and to track disease progression. Previous studies have reported a specific decrease of nigral fractional anisotropy in PD. However, to date the effect of disease progression on nigral or striatal diffusion indices has not been fully explored. METHODS: We have conducted a cross-sectional and longitudinal diffusion tensor imaging study in 18 early stage, treated PD patients and 14 age-matched controls. PD patients were scanned on 2 occasions OFF medication, 19.3 months apart (standard deviation = 3.1 months). Longitudinal change of regional nigral and striatal measures of fractional anisotropy and mean diffusivity were calculated using a region-of-interest approach. RESULTS: Region-of-interest analysis demonstrated that at baseline, PD patients and controls did not differ in regard to diffusion indices in any region assessed. A significant difference of nigral fractional anisotropy and mean diffusivity between controls and PD patients at follow-up was detected and confirmed with longitudinal analysis within PD patients. Alterations in striatal regions were not detected in either group or over time. CONCLUSION: Our findings indicate that nigral diffusion measure may be a valuable measure of disease progression. In the future, larger longitudinal studies will confirm whether diffusion indices may serve as sensitive and clinically meaningful measures of disease progression in PD.
BACKGROUND: Measuring microstructure alterations with diffusion tensor imaging in PD is potentially a valuable tool to use as a biomarker for early diagnosis and to track disease progression. Previous studies have reported a specific decrease of nigral fractional anisotropy in PD. However, to date the effect of disease progression on nigral or striatal diffusion indices has not been fully explored. METHODS: We have conducted a cross-sectional and longitudinal diffusion tensor imaging study in 18 early stage, treated PD patients and 14 age-matched controls. PD patients were scanned on 2 occasions OFF medication, 19.3 months apart (standard deviation = 3.1 months). Longitudinal change of regional nigral and striatal measures of fractional anisotropy and mean diffusivity were calculated using a region-of-interest approach. RESULTS: Region-of-interest analysis demonstrated that at baseline, PD patients and controls did not differ in regard to diffusion indices in any region assessed. A significant difference of nigral fractional anisotropy and mean diffusivity between controls and PD patients at follow-up was detected and confirmed with longitudinal analysis within PD patients. Alterations in striatal regions were not detected in either group or over time. CONCLUSION: Our findings indicate that nigral diffusion measure may be a valuable measure of disease progression. In the future, larger longitudinal studies will confirm whether diffusion indices may serve as sensitive and clinically meaningful measures of disease progression in PD.
Authors: Vincent Pozorski; Jennifer M Oh; Nagesh Adluru; Andrew P Merluzzi; Frances Theisen; Ozioma Okonkwo; Amy Barzgari; Stephanie Krislov; Jitka Sojkova; Barbara B Bendlin; Sterling C Johnson; Andrew L Alexander; Catherine L Gallagher Journal: Hum Brain Mapp Date: 2018-06-27 Impact factor: 5.038
Authors: Fabiana C C Hirata; João R Sato; Gilson Vieira; Leandro T Lucato; Claudia C Leite; Edson Bor-Seng-Shu; Bruno F Pastorello; Maria C G Otaduy; Khallil T Chaim; Kenia R Campanholo; Natalia P Novaes; Luciano Magalhães Melo; Márcia R Gonçalves; Felipe Barjud Pereira do Nascimento; Manoel Jacobsen Teixeira; Egberto Reis Barbosa; Edson Amaro; Ellison Fernando Cardoso Journal: Eur Radiol Date: 2016-10-05 Impact factor: 5.315
Authors: T Guttuso; N Bergsland; J Hagemeier; D G Lichter; O Pasternak; R Zivadinov Journal: AJNR Am J Neuroradiol Date: 2018-02-01 Impact factor: 3.825
Authors: Yulia Surova; Markus Nilsson; Björn Lampinen; Jimmy Lätt; Sara Hall; Håkan Widner; Danielle van Westen; Oskar Hansson Journal: Neuroradiology Date: 2018-01-24 Impact factor: 2.804
Authors: Jae Woo Chung; Roxana G Burciu; Edward Ofori; Priyank Shukla; Michael S Okun; Christopher W Hess; David E Vaillancourt Journal: Neuroimage Clin Date: 2017-02-16 Impact factor: 4.881